Allergan plc (NYSE:AGN) updated its FY17 earnings guidance on Tuesday. The company provided EPS guidance of $15.85-16.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.01.
Allergan plc (NYSE:AGN) traded up 0.75% on Friday, hitting $220.38. 1,880,186 shares of the stock traded hands. Allergan plc has a 1-year low of $184.50 and a 1-year high of $261.27. The stock has a 50-day moving average price of $237.03 and a 200 day moving average price of $222.48. The company has a market cap of $74.02 billion, a price-to-earnings ratio of 6.87 and a beta of 1.07.
Allergan plc (NYSE:AGN) last released its quarterly earnings data on Tuesday, May 9th. The company reported $3.35 EPS for the quarter, beating the consensus estimate of $3.32 by $0.03. Allergan plc had a return on equity of 7.21% and a net margin of 100.04%. The company had revenue of $3.57 billion for the quarter, compared to analysts’ expectations of $3.53 billion. During the same period last year, the firm posted $3.04 earnings per share. Allergan plc’s revenue was up 5.1% compared to the same quarter last year. On average, analysts anticipate that Allergan plc will post $16.10 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Shareholders of record on Thursday, May 18th will be given a $0.70 dividend. The ex-dividend date of this dividend is Tuesday, May 16th. This represents a $2.80 annualized dividend and a yield of 1.28%.
Several analysts recently issued reports on AGN shares. Leerink Swann set a $271.00 target price on Allergan plc and gave the company a buy rating in a research note on Thursday, February 2nd. Deutsche Bank AG lifted their target price on Allergan plc from $262.00 to $265.00 and gave the stock a buy rating in a report on Tuesday, March 28th. Vetr cut Allergan plc from a buy rating to a hold rating and set a $228.27 target price for the company. in a report on Wednesday, February 1st. Credit Suisse Group AG restated a buy rating and set a $274.00 price objective on shares of Allergan plc in a report on Tuesday, February 14th. Finally, Royal Bank of Canada reaffirmed a buy rating and set a $279.00 target price on shares of Allergan plc in a research report on Tuesday, March 14th. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $267.21.
In other Allergan plc news, Director Paul Bisaro sold 70,000 shares of Allergan plc stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $246.68, for a total value of $17,267,600.00. Following the sale, the director now owns 274,226 shares of the company’s stock, valued at approximately $67,646,069.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/19/allergan-plc-agn-issues-fy17-earnings-guidance-updated.html.
Several large investors have recently modified their holdings of the stock. First Financial Equity Corporation bought a new stake in shares of Allergan plc during the first quarter worth about $465,000. Green Square Capital LLC raised its stake in shares of Allergan plc by 3.6% in the first quarter. Green Square Capital LLC now owns 5,916 shares of the company’s stock valued at $1,413,000 after buying an additional 203 shares during the last quarter. RBF Capital LLC purchased a new stake in shares of Allergan plc during the first quarter valued at approximately $1,672,000. Altavista Wealth Management Inc. boosted its position in Allergan plc by 16.0% in the first quarter. Altavista Wealth Management Inc. now owns 16,105 shares of the company’s stock valued at $3,848,000 after buying an additional 2,223 shares during the period. Finally, Covington Capital Management boosted its position in Allergan plc by 12.7% in the first quarter. Covington Capital Management now owns 24,818 shares of the company’s stock valued at $5,930,000 after buying an additional 2,788 shares during the period. Institutional investors and hedge funds own 86.40% of the company’s stock.
Allergan plc Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.